Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
Metastatic Melanoma|Melanoma|BRAF-mutated Metastatic Melanoma|V600EBRAF-mutated Metastatic Melanoma
DRUG: Vemurafenib + Cobimetinib, Decitabine
Dose-limiting toxicities per CTCAE 4.0, Toxicity will be assessed using the NIH-NCI Common Terminology Criteria for Adverse Events, version 4.0 (CTCAEv4). Toxicity will be decided after administration of one full cycle for patients., From Day 1 - 28 of a 28 day cycle
The primary objective of the Phase I portion of this study is to evaluate the safety and tolerability of the proposed schedule of decitabine and Vemurafenib plus Cobimetinib in the treatment of metastatic melanoma.